Peptron files an IND for PT403, a SmartDepot-based once-monthly semaglutide formulation, advancing the obesity treatment into Phase 1 clinical development.
Written By: Khushi Patel, PharmD
Reviewed By: Pharmacally Editorial Team
Peptron has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety (MFDS) for PT403, a long-acting injectable formulation of semaglutide developed with its SmartDepot™ technology. The filing marks PT403’s entry into formal clinical evaluation to determine whether the established obesity and diabetes therapeutic can be successfully delivered as a once-monthly treatment.
SmartDepot™ Approach Extends an Established Therapeutic
Semaglutide is an established GLP-1 receptor agonist, but existing commercial formulations require weekly administration. PT403 applies Peptron’s SmartDepot™ platform to create a sustained-release formulation intended to maintain therapeutic drug exposure over an extended dosing interval.
Rather than developing a novel active molecule, Peptron is applying its proprietary delivery platform to an ingredient with extensive clinical and commercial experience. This provides a well-characterized pharmacological foundation, while PT403’s formulation-specific safety, tolerability and pharmacokinetic profile must now be established in human trials. Reducing injection frequency could also improve treatment convenience and adherence in long-term metabolic care.
Phase 1 Trial Design
The planned Phase 1 study will enroll 22 healthy adults across three cohorts. Participants will receive a single subcutaneous dose of PT403 in a stepwise, dose-escalation design, with cohort progression guided by sequential safety reviews.
The trial will systematically characterize PT403’s safety, tolerability, and pharmacokinetic behavior. These data will offer the first formal clinical evidence on whether the SmartDepot™ formulation can support a once-monthly dosing profile.
ADA 2026 Findings Pave Way for IND
The IND filing builds on preclinical and pilot clinical studies presented at the American Diabetes Association (ADA) 2026 Scientific Sessions in June. While those initial findings provided early proof-of-concept, the Phase 1 program represents the formal clinical evaluation needed to characterize PT403 in humans.
Next Steps in Development
Results from the Phase 1 trial will guide future dose selection and shape the program’s broader development strategy. Peptron intends to use these data as the foundation for potential global development, where the central objective will be confirming that SmartDepot™ sustains therapeutic semaglutide levels over a monthly interval with an acceptable tolerability profile.
Reference
About the Writer
Khushi Patel is a Pharm.D (Linkedin) professional with a strong foundation in clinical pharmacy, patient-centered care, regulatory affairs, and pharmacovigilance, with published work on Brugada syndrome.
Her interests include regulatory affairs, pharmacovigilance, guideline integration, multimodal therapy, pharmacogenomics, and antibiogram utilization, with a focus on evidence-based clinical decision-making and medication safety.
As a Pharmacally healthcare writer, she translates clinical and scientific evidence into clear, accurate, and clinically relevant healthcare content, while continuously developing her expertise in evolving pharmacy practice.